---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-023933"
form_type: "8-K"
ticker: "ENSC"
cik: "0001716947"
company_name: "Ensysce Biosciences, Inc."
filed_at: "2025-11-17T23:59:59+00:00"
generated_at: "2026-05-16T19:20:12.122659+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ensysce Biosciences closes $4M convertible preferred stock financing with up to $20M available

## Summary
- Closed $4M convertible preferred stock financing; up to $16M additional available in future tranches over 24 months.
- Conversion price fixed at $2.50/share; 50% warrant coverage exercisable at same price for five years.
- Proceeds to accelerate Phase 3 clinical development of PF614, a novel abuse-resistant analgesic.
- Series B preferred pays 4% annual dividend (8% on triggering events); stated value $1,100 per share.
- Net proceeds from the offerings estimated at ~$3.6 million for general corporate purposes and working capital.

## SEC filing metadata
- accession: 0001493152-25-023933
- form_type: 8-K
- ticker: ENSC
- cik: 0001716947
- company_name: Ensysce Biosciences, Inc.
- filed_at: 2025-11-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716947/000149315225023933/0001493152-25-023933-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716947/000149315225023933/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-023933
- JSON: https://secwatch.observer/filing/0001493152-25-023933.json
- Plain text: https://secwatch.observer/filing/0001493152-25-023933.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.